About: The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial
Creator	Incorvaia, Cristoforo Melioli, Giovanni Canonica, Giorgio Rossi, Oliviero Accorsi, Carlo Baiardini, Ilaria Bonzano, Laura Bossilino, Claudia Braido, Fulvio Candoli, Piero Cavalot, Andrea Di Marco, Eddi Dilizia, Michela Fedrighini, Barbara Ferrero, Vittorio Gioacchino, Mario Garelli, Valentina Gerace, Vincenzo Maniscalco, Sara Massaro, Ilaria Mereu, Carlo Messi, Alessandro Milanese, Manlio Penno, Arminio Peveri, Silvia Pizzimenti, Stefano Pozzo, Tiziana Raie, Alberto Rolla, Giovanni Reggiardo, Giorgio Regina, Sergio Ridolo, Erminia Rinaldi, Gilberto Savi, Eleonora Sclifò, Francesca Tubino, Libero
Source	Elsevier; Medline; PMC
abstract	Abstract Studies in the 1970s and 1980s reported that bacterial lysates (BL) had a prophylactic effect on recurrent respiratory tract infections (RRTI). However, controlled clinical study procedures have evolved substantially since then. We performed a trial using updated methods to evaluate the efficacy of Lantigen B®, a chemical BL. This double blind, placebo controlled, multi-center clinical trial had the primary objective of assessing the capacity of Lantigen B to significantly reduce the total number of infectious episodes in patients with RRTI. Secondary aims were the RRTI duration, the frequency and the severity of the acute episodes, the use of drugs and the number of missed workdays. In the subgroup of allergic patients with RRTI, the number of allergic episodes (AE) and the use of anti-allergic drugs were also evaluated. One hundred and sixty patients, 79 allocated to the treated group (TG) and 81 to the placebo group (PG), were enrolled; 30 were lost during the study and 120 (79 females and 38 males) were evaluated. The PG had 1.43 episodes in the 8-months of follow-up while the TG had 0.86 episodes (p =0.036). A similar result was observed in the allergic patients (1.80 and 0.86 episodes for the PG and the TG, respectively, p =0.047). The use of antibiotics was reduced (mean 1.24 and 2.83 days of treatment for the TG and the PG). Logistic regression analysis indicated that the estimated risk of needing antibiotics and NSAIDs was reduced by 52.1 and 30.6%, respectively. With regard to the number of AE, no significant difference was observed between the two groups, but bronchodilators, antihistamines and local corticosteroids were reduced by 25.7%, 56.2% and 41.6%, respectively, in the TG. Lantigen B significantly reduced the number of infectious episodes in patients with RRTI. This finding suggests a first line use of this drug for the prophylaxis of infectious episodes in these patients.
has issue date	2014-12-31(xsd:dateTime)
bibo:doi	10.1016/j.imlet.2014.10.026
bibo:pmid	25445613
has license	els-covid
sha1sum (hex)	ad5032e9d718b41dcc9fa71e309b82661d2c53a6
schema:url	https://doi.org/10.1016/j.imlet.2014.10.026
resource representing a document's title	The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial
has PubMed Central identifier	PMC7173099
has PubMed identifier	25445613
schema:publication	Immunology Letters
resource representing a document's body	covid:ad5032e9d718b41dcc9fa71e309b82661d2c53a6#body_text
is schema:about of	named entity 'objective' named entity 'drugs' named entity 'group' covid:arg/ad5032e9d718b41dcc9fa71e309b82661d2c53a6 named entity 'placebo' named entity 'group' named entity 'double blind' named entity 'episodes' named entity 'acute' named entity 'allergic' named entity 'bacterial' named entity 'procedures' named entity 'clinical trial' named entity 'controlled' named entity 'bacterial' named entity 'follow-up' named entity 'allergic' named entity 'placebo controlled' named entity 'statistically significant' named entity 'pharmacologically' named entity 'lysates' named entity 'chlorhexidine' named entity 'clinical study' named entity 'asthma' named entity 'antihistamine' named entity 'interferons' named entity 'cough' named entity 'bronchitis' named entity 'rhonchi' named entity 'SAS Institute' named entity 'ANCOVA' named entity 'adverse reactions' named entity 'logistic regression' named entity 'European Medicine Agency' named entity 'immunological disorders' named entity 'flu virus' named entity 'pharmacological' named entity 'controlled clinical trials' named entity 'Staphylococcus aureus' named entity 'allergy' named entity 'placebo' named entity 'placebo' named entity 'anti-allergic' named entity 'allergic' named entity 'adverse reaction' named entity 'dendritic cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software